BiotechTube

eltrombopag olamine (SB-497115-GR)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Purpura, Thrombocytopaenic, Idiopathic

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Trial Timeline

Jun 1, 2006 → Jul 1, 2015

NCT ID
NCT00351468

About eltrombopag olamine (SB-497115-GR)

eltrombopag olamine (SB-497115-GR) is a phase 3 stage product being developed by Novartis for Purpura, Thrombocytopaenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT00351468. Target conditions include Purpura, Thrombocytopaenic, Idiopathic.

What happened to similar drugs?

1 of 20 similar drugs in Purpura, Thrombocytopaenic, Idiopathic were approved

Approved (1) Terminated (1) Active (18)
❌Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
🔄Hetrombopag Olamine + matching placeboJiangsu Hengrui MedicinePhase 3
🔄EltrombopagNovartisPhase 3
🔄eltrombopag + placeboNovartisPhase 3
🔄Eltrombopag + IVIG infusionNovartisPhase 3
🔄Eltrombopag Tablets + Eltrombopag PfOSNovartisPhase 3
🔄rituximab + DexamethasoneRochePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00351468Phase 3Completed

Competing Products

20 competing products in Purpura, Thrombocytopaenic, Idiopathic

See all competitors
ProductCompanyStageHype Score
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oralEisaiPhase 1
29
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Hetrombopag Olamine + matching placeboJiangsu Hengrui MedicinePhase 3
40
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
25
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
25
MK-8723 + Matching PlaceboMerckPhase 1
29
EltrombopagNovartisPhase 2
35
eltrombopagNovartisPhase 2
35
EltrombopagNovartisPre-clinical
26
EltrombopagNovartisPhase 3
36
eltrombopag + placeboNovartisPhase 3
40
Eltrombopag + IVIG infusionNovartisPhase 3
40
Eltrombopag Tablets + Eltrombopag PfOSNovartisPhase 3
40